MedTrace Logo

VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.

NCT04988997 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-12-20

No results posted yet for this study

Summary

A Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.

Conditions

  • Short Bowel Syndrome

Interventions

DRUG

Vurolenatide 50mg/PBO

Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks

DRUG

Vurolenatide 100mg/PBO

Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks

DRUG

Vurolenatide 50/50 mg

Vurolenatide - 50 mg weekly SC administration

DRUG

Placebo

PBO - weekly SC administration

Sponsors & Collaborators

  • 9 Meters Biopharma, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-14
Primary Completion
2022-08-05
Completion
2022-08-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04988997 on ClinicalTrials.gov